Galectin Therapeutics to Present at BIO CEO & Investor Conference
09 February 2017 - 12:30AM
Galectin Therapeutics Inc. (NASDAQ:GALT), the
leading developer of therapeutics that target galectin proteins,
today announced that Harold Shlevin, Ph.D., the Company’s chief
operating officer, will present at BIO CEO & Investor
Conference on Monday, February 13, 2017 at 3:00 p.m. Eastern time.
The conference is being held at the Waldorf Astoria in New York
City on February 13-14, 2017.
A live webcast of the 25-minute presentation may be accessed on
the conference’s website
at http://www.veracast.com/webcasts/bio/ceoinvestor2017/86126440478.cfm
with the ability to replay 1 hour after the conclusion of the
webcast. The webcast and presentation will be archived for 90 days
following the event on the company’s website at
www.galectintherapeutics.com.
About Galectin Therapeutics Galectin
Therapeutics is developing promising carbohydrate-based
therapies for the treatment of fibrotic liver disease and cancer
based on the Company's unique understanding of galectin proteins,
which are key mediators of biologic function. Galectin seeks to
leverage extensive scientific and development expertise as well as
established relationships with external sources to achieve
cost-effective and efficient development. The Company is pursuing a
development pathway to clinical enhancement and commercialization
for its lead compounds in liver fibrosis and cancer. Additional
information is available
at www.galectintherapeutics.com.
Contacts:
Jack Callicutt, Chief Financial Officer
(678) 620-3186
ir@galectintherapeutics.com.
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Apr 2024 to May 2024
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From May 2023 to May 2024